Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Utah |
---|---|
Information provided by: | University of Utah |
ClinicalTrials.gov Identifier: | NCT00361972 |
We propose to study how heartburn may lead to different types of inflammation in one's airways. Additionally, we hope to determine whether aggressive treatment of heartburn results in improvement in both symptoms of heartburn and asthma but also in documented improvement in airway inflammation as determined by biopsy. The results of this study will be important in directing future research into the relationship between heartburn and asthma and may provide a clue whether certain subtypes of asthma may be caused primarily by GER.
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux Asthma |
Drug: lansoprazole Drug: placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Elucidation of Acid-Induced Pulmonary Inflammation |
Estimated Enrollment: | 30 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: lansoprazole
30 mg of placebo or lansoprazole twice daily for 2-4 months
|
2: Placebo Comparator
placebo
|
Drug: placebo
placebo comparator to lansoprazole, 30 mg, twice a day
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Subjects with contraindications to pH/impedance probe
Contact: Kristen L Thomas, BS | 801-587-9854 | kristen.thomas@hsc.utah.edu |
Contact: Kristen Hilden, MS | 801-581-3693 | kristen.thomas@hsc.utah.edu |
United States, Utah | |
University of Utah Health Sciences Center | Recruiting |
Salt Lake City, Utah, United States, 84132 | |
Contact: Kristen L Thomas, BS 801-587-9854 kristen.thomas@hsc.utah.edu | |
Contact: kristen Hilden, MS 801-581-3693 kristen.hilden@hsc.utah.edu | |
Principal Investigator: Kathryn A Peterson, MD, MSci | |
Sub-Investigator: Mae Go, MD | |
Sub-Investigator: David Young, PharmD | |
Sub-Investigator: Wayne Samuelson, MD |
Principal Investigator: | Kathryn Peterson, MD | University of Utah |
Responsible Party: | University of Utah HSC ( Kathryn A. Peterson, M.D. ) |
Study ID Numbers: | 15444, IRB #15444 |
Study First Received: | August 8, 2006 |
Last Updated: | October 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00361972 |
Health Authority: | United States: Institutional Review Board |
Esophageal disorder Gastrointestinal Diseases Asthma Gastroesophageal Reflux Inflammation Esophageal Motility Disorders Deglutition Disorders |
Digestive System Diseases Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases Lansoprazole Esophageal Diseases Pneumonia |
Anti-Infective Agents Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Anti-Ulcer Agents Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |